^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Turalio (pexidartinib)

    i
    Other names: PLX3397, PLX-3397, PLX 3397
    Company:
    Daiichi Sankyo
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    Apply
    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... (NCT02390752)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    04/29/2015
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    NF1
    |
    Turalio (pexidartinib)
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • ganetespib (ADX-1612) • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • Veppanu (vepdegestrant) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • Oraxol (oral paclitaxel/encequidar) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma (NCT02975700)
    Phase N/A
    Daiichi Sankyo Co., Ltd.
    Active, not recruiting
    Last update posted :
    04/10/2024
    Initiation :
    01/31/2017
    Primary completion :
    08/31/2018
    Completion :
    03/31/2025
    KIT
    |
    KIT mutation
    |
    Turalio (pexidartinib)
    PLX3397 KIT in Acral aNd mucOsal Melanoma (PIANO) (NCT02071940)
    Phase 2
    The Christie NHS Foundation Trust
    Completed
    Last update posted :
    08/12/2021
    Initiation :
    10/01/2015
    Primary completion :
    03/02/2021
    Completion :
    03/02/2021
    KIT
    |
    KIT mutation
    |
    Turalio (pexidartinib)
    Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics) (NCT03291288)
    Phase 1
    Daiichi Sankyo, Inc.
    Completed
    Last update posted :
    05/14/2021
    Initiation :
    02/26/2018
    Primary completion :
    09/26/2018
    Completion :
    04/16/2021
    KIT
    |
    Turalio (pexidartinib) • midazolam hydrochloride
    A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) (NCT03158103)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    04/30/2021
    Initiation :
    04/15/2017
    Primary completion :
    04/28/2021
    Completion :
    04/28/2021
    KIT • PDGFRA
    |
    PDGFR wild-type
    |
    Mektovi (binimetinib) • Turalio (pexidartinib)
    Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (NCT01596751)
    Phase 1/2
    Hope Rugo, MD
    Completed
    Last update posted :
    07/17/2020
    Initiation :
    07/12/2012
    Primary completion :
    07/05/2017
    Completion :
    07/05/2019
    HER-2 • PGR
    |
    HER-2 overexpression • HER-2 negative
    |
    eribulin mesylate • Turalio (pexidartinib)
    Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT01349049)
    Phase 1/2
    Daiichi Sankyo, Inc.
    Completed
    Last update posted :
    03/02/2020
    Initiation :
    11/21/2011
    Primary completion :
    01/20/2015
    Completion :
    01/09/2018
    FLT3
    |
    FLT3-ITD mutation
    |
    Turalio (pexidartinib)